Lyell Immunopharma, Inc.
NASDAQ:LYELBiotechnology
+$0.15 today
- Market cap
- $341.49M
- Beta
- -0.09
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$11.26
Volume 0.11M
Average 0.09M
LYEL Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Lyell Immunopharma, Inc.NASDAQ: LYEL
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns positive
Q1 FY2026 accounts payables was $2.38M, compared with -$1.65M a year earlier. Trailing-twelve-month accounts payables was $1.7M.
Context
- Accounts payables amounted to 6497.2% of revenue in FY2025, up 1195.6 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $2.38M or moves back toward the trailing-twelve-month quarterly average of $424.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (2.34M) USD
- Year-over-year change
- +27.7%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.34M) | +27.7% |
| FY2024 | 2024-12-31 | (3.23M) | -320.9% |
| FY2023 | 2023-12-31 | 1.46M | +119.5% |
| FY2022 | 2022-12-31 | 667K | +633.0% |
| FY2021 | 2021-12-31 | 91K | — |
Accounts Payables vs competitors
How LYEL compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +135.6% is the 2nd highest of 9, against a peer median of -17.8%.
- Accounts payables amounts to 5477.4% of revenue for LYEL, versus a peer median of 9.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.22M USD | +128.8% | — | 8.0% | |
| LTM Mar 2026 | $5.87M USD | +736.9% | +375.3% | — | |
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $3.03M USD | +109.0% | -7.1% | — | |
| LTM Mar 2026 | $1.7M USD | +135.6% | — | 5477.4% | |
| LTM Mar 2026 | $1.13M USD | +32.3% | — | 2.9% | |
GNLXGenelux Corporation | LTM Mar 2026 | $594K USD | -134.0% | — | 7425.0% |
| LTM Dec 2025 | CHF 327.34K CHF | — | — | 9.2% | |
| LTM Mar 2026 | $310K USD | -132.7% | — | — | |
| LTM Mar 2026 | $232K USD | -67.8% | — | — | |
| LTM Mar 2026 | $204.79K USD | -411.0% | -70.8% | — | |
| Peer median (excluding LYEL) | — | -17.8% | -7.1% | 9.2% | |
Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (250.22M) | (183.12M) | (234.63M) | (342.99M) | (274.45M) |
| Depreciation & Amortization | 13.62M | 16.47M | 20.25M | 19.63M | 11.54M |
| Deferred Income Tax | 39.51M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 62.2M | 0 | 47.08M | 33.14M | 41.83M |
| Change in Working Capital | 4.02M | (82.02M) | 3.42M | (3.12M) | (9.89M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 91K | 667K | 1.46M | (3.23M) | (2.34M) |
| Other Working Capital | 3.92M | (82.68M) | 1.96M | 114K | (7.56M) |
| Other Non-Cash Items | 4.62M | 79.11M | 183K | 130.95M | 80.95M |
| Operating Cash Flow | (126.25M) | (169.56M) | (163.69M) | (162.39M) | (150.02M) |
| Capital Expenditures | (65.5M) | (24.28M) | (2.69M) | (464K) | (780K) |
| Acquisitions (Net) | 673.47M | 0 | 0 | (31.35M) | (41.2M) |
| Purchases of Investments | (673.47M) | (406.32M) | (476.88M) | (394.71M) | (259.71M) |
| Sales of Investments | 617.4M | 419.05M | 663.61M | 548.94M | 374.68M |
| Other Investing Activities | (673.47M) | 0 | 0 | 0 | (18.9M) |
| Investing Cash Flow | (121.57M) | (11.54M) | 184.05M | 122.42M | 54.1M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 391.8M | 11.1M | 2.2M | 1.4M | 50.41M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 9.44M | (461K) | (457K) | (76K) | (1K) |
| Financing Cash Flow | 401.24M | 10.64M | 1.74M | 1.33M | 50.41M |
| Effect of Forex Changes | 0 | 186K | (4K) | 0 | 0 |
| Net Change in Cash | 153.42M | (170.27M) | 22.09M | (38.64M) | (45.52M) |
| Free Cash Flow | (191.75M) | (193.83M) | (166.38M) | (162.86M) | (150.8M) |
Lyell Immunopharma, Inc.
NASDAQ:LYEL
Intrinsic Alpha fair value
Locked
Current Price
$13.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.